In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Dr Collins discusses the significant shifts in treatment approaches for patients with advanced-stage classical Hodgkin lymphoma over the past decade. He also explores the excitement around newer regimens, including nivolumab-AVD, BV-AVD, and more. To conclude, Dr Collins shares his approach to treating patients with relapsed disease, drawing focus on the role of autologous stem cell transplantation.

Today's VJHemOnc podcast features discussions from the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025, which was held recently in Miami, FL. First you will hear from Elizabeth Budde, MD, PhD, City of Hope, Duarte, CA, Mohammad Rashidian, PhD, Dana-Farber Cancer Institute, Boston, MA, Michael Jain, MD, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, and Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, who explore outcomes of treatment with CAR T-cells and potential strategies to enhance their efficacy and minimize toxicities.

Michael Hudecek, MD, University of Würzburg, Würzburg, Germany, then provides insight into his keynote talk on accelerating CAR T-cell therapeutics with small molecules and CRISPR 2.0 gene editing. This is followed by Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Tara Graff, DO, MS, Mission Cancer and Blood, Des Moines, IA, and Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA, who share their perspectives on how to improve access and delivery of T-cell engaging therapies in the community.